Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16815732 | 1.00 | KMT2A (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL8953561 | 1.00 | KMT2A (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL7516087 | 1.00 | KMT2A (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL10830353 | 0.85 | HTT (0.48) | KMT2AMEN1ALDH1A1GAACRHBP | |
| SCHEMBL28019826 | 0.85 | HPGD (0.50) | KMT2AMEN1ALDH1A1GAAHPGD | |
| SCHEMBL7385695 | 0.84 | CYP1A2 (0.59) | KMT2AMEN1ALDH1A1GAACRHBP | |
| SCHEMBL8953568 | 0.84 | CYP1A2 (0.45) | KMT2AMEN1ALDH1A1GAACRHBP | |
| SCHEMBL1419560 | 0.83 | KMT2A (0.53) | KMT2AMEN1ALDH1A1GAACRHBP | |
| SCHEMBL16815475 | 0.82 | MEN1 (0.48) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL18342037 | 0.82 | CYP1A2 (0.48) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116602-A1 | MCL1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| CN-114746428-A | MCL1 inhibitor and application thereof | 加利福尼亚技术学院 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021067827-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2015097123-A1 | NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-07-02 | — | — | WO | disclosed |
| US-20120021061-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | COMVITA NEW ZEALAND LIMITED (NZ) | 2012-01-26 | — | — | US | disclosed |
| EP-2367444-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | Comvita New Zealand Limited (NZ) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010082846-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | COMVITA NEW ZEALAND LIMITED (NZ) | 2010-07-22 | — | — | WO | disclosed |
| EP-0634408-B1 | DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| CN-1039331-C | Depsispeptide derivative, preparation and application of same | FUJISAMA PHARMACEUTICAL CO LTD (JP) | 1998-07-29 | — | — | CN | disclosed |
| US-5514773-A | PARASITICIDES, ANTHELMINTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-07 | — | — | US | disclosed |
| EP-0634408-A1 | DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-18 | — | — | EP | disclosed |
| CN-1080932-A | Depsipeptide derivative and manufacture method thereof and purposes | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021061-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | FABP6, NNT, IAPP | KMT2A 3315/4885MEN1 276/4885ALDH1A1 2943/4885 |
| US-20230116602-A1 | MCL1 INHIBITORS AND USES THEREOF | MCL1, BCL2L1, BCL2L11 | KMT2A 2368/4885MEN1 399/4885ALDH1A1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.